Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRNX Crinetics Pharmaceuticals	$34.73 -0.5%	$36.02	$31.84 ▼ $62.53	$3.23B	0.58	830,038 shs	690,164 shs
PHVS Pharvaris	$15.80 +1.5%	$16.73	$14.14 ▼ $25.50	$826.18M	-3.02	72,293 shs	35,808 shs
PTGX Protagonist Therapeutics	$48.88 -1.1%	$42.54	$24.22 ▼ $60.60	$3.00B	2.34	796,889 shs	664,503 shs
SRRK Scholar Rock	$32.84 -1.6%	$37.74	$6.76 ▼ $46.98	$3.11B	0.59	1.17 million shs	1.13 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRNX Crinetics Pharmaceuticals	0.00%	+0.90%	+4.58%	-33.02%	-21.83%
PHVS Pharvaris	0.00%	+2.60%	+1.54%	-18.68%	-32.77%
PTGX Protagonist Therapeutics	0.00%	-7.16%	+34.51%	+25.46%	+71.63%
SRRK Scholar Rock	0.00%	-0.64%	-8.68%	-26.14%	+112.56%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRNX Crinetics Pharmaceuticals	4.3746 of 5 stars	4.5	2.0	3.7	3.3	2.5	0.0
PHVS Pharvaris	1.5352 of 5 stars	3.5	1.0	0.0	2.7	0.8	0.0
PTGX Protagonist Therapeutics	3.5975 of 5 stars	4.5	1.0	0.0	3.4	2.5	1.3
SRRK Scholar Rock	3.9922 of 5 stars	3.5	0.0	4.4	2.7	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRNX Crinetics Pharmaceuticals	2.92	Moderate Buy	$73.00	110.19% Upside
PHVS Pharvaris	3.00	Buy	$40.50	156.33% Upside
PTGX Protagonist Therapeutics	3.00	Buy	$62.56	27.98% Upside
SRRK Scholar Rock	3.00	Buy	$42.67	29.92% Upside

Current Analyst Ratings Breakdown

Latest PHVS, PTGX, CRNX, and SRRK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/28/2025	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00 ➝ $70.00
3/25/2025	CRNX Crinetics Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
3/25/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
3/17/2025	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00
3/11/2025	PTGX Protagonist Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$70.00
3/11/2025	PTGX Protagonist Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $76.00
3/11/2025	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$62.00 ➝ $72.00
3/10/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $54.00
3/4/2025	PTGX Protagonist Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$53.00 ➝ $57.00
3/3/2025	PTGX Protagonist Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$73.00
3/3/2025	PTGX Protagonist Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $54.00

(Data available from 3/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRNX Crinetics Pharmaceuticals	$1.04M	3,110.29	N/A	N/A	$8.07 per share	4.30
PHVS Pharvaris	N/A	N/A	N/A	N/A	$7.95 per share	N/A
PTGX Protagonist Therapeutics	$434.43M	6.91	N/A	N/A	$5.84 per share	8.37
SRRK Scholar Rock	$33.19M	93.68	N/A	N/A	$3.12 per share	10.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.71	N/A	N/A	N/A	N/A	-36.12%	-31.89%	5/8/2025 (Estimated)
PHVS Pharvaris	-$109.18M	-$2.80	N/A	N/A	N/A	N/A	-38.52%	-36.69%	4/9/2025 (Estimated)
PTGX Protagonist Therapeutics	-$78.96M	$4.20	18.38	N/A	N/A	52.76%	34.68%	30.98%	5/6/2025 (Estimated)
SRRK Scholar Rock	-$165.79M	-$2.45	N/A	N/A	N/A	N/A	-145.60%	-91.83%	5/6/2025 (Estimated)

Latest PHVS, PTGX, CRNX, and SRRK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/9/2025	N/A	PHVS Pharvaris	-$0.74	N/A	N/A	N/A	N/A	N/A
2/27/2025	Q4 2024	CRNX Crinetics Pharmaceuticals	-$0.92	-$0.88	+$0.04	-$0.88	$0.73 million	N/A
2/21/2025	Q4 2024	PTGX Protagonist Therapeutics	-$0.09	$1.98	+$2.07	$1.98	$56.65 million	$170.64 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PHVS Pharvaris	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
PHVS Pharvaris	N/A	19.08	19.08
PTGX Protagonist Therapeutics	N/A	10.69	10.70
SRRK Scholar Rock	0.63	3.88	3.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRNX Crinetics Pharmaceuticals	98.51%
PHVS Pharvaris	N/A
PTGX Protagonist Therapeutics	98.63%
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CRNX Crinetics Pharmaceuticals	6.00%
PHVS Pharvaris	11.84%
PTGX Protagonist Therapeutics	5.40%
SRRK Scholar Rock	19.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRNX Crinetics Pharmaceuticals	210	93.05 million	87.17 million	Optionable
PHVS Pharvaris	30	52.29 million	46.10 million	Not Optionable
PTGX Protagonist Therapeutics	120	61.38 million	56.38 million	Optionable
SRRK Scholar Rock	140	94.68 million	75.64 million	Optionable

PHVS, PTGX, CRNX, and SRRK Headlines

Recent News About These Companies

American Century Companies Inc. Acquires New Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 30 at 3:45 AM | marketbeat.com

Raymond James Financial Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 30 at 3:15 AM | marketbeat.com

Loomis Sayles & Co. L P Makes New Investment in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 29 at 5:47 AM | marketbeat.com

BIT Capital GmbH Decreases Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 28 at 6:31 AM | marketbeat.com

Scholar Rock Announces FDA Priority Review Designation For Apitegromab - Quick Facts

March 27 at 11:33 AM | nasdaq.com

FDA accepts Scholar Rock BLA for apitegromab under priority review to treat SMA

March 27 at 11:33 AM | markets.businessinsider.com

Insider Selling: Scholar Rock Holding Co. (NASDAQ:SRRK) Insider Sells 6,500 Shares of Stock

March 26, 2025 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Receives "Outperform" Rating from Wedbush

March 26, 2025 | marketbeat.com

Swiss National Bank Boosts Stock Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 25, 2025 | marketbeat.com

Victory Capital Management Inc. Takes Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 23, 2025 | marketbeat.com

AlphaQuest LLC Sells 34,414 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

March 21, 2025 | marketbeat.com

Scholar Rock Holding Co. (NASDAQ:SRRK) Director Katie Peng Sells 1,006 Shares

March 20, 2025 | marketbeat.com

54,717 Shares in Scholar Rock Holding Co. (NASDAQ:SRRK) Bought by Proficio Capital Partners LLC

March 19, 2025 | marketbeat.com

Wedbush Reaffirms "Outperform" Rating for Scholar Rock (NASDAQ:SRRK)

March 18, 2025 | marketbeat.com

Skandinaviska Enskilda Banken AB publ Buys Shares of 28,599 Scholar Rock Holding Co. (NASDAQ:SRRK)

March 18, 2025 | marketbeat.com

Charles Schwab Investment Management Inc. Purchases 119,616 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK)

March 18, 2025 | marketbeat.com

TD Cowen Reaffirms Their Buy Rating on Scholar Rock Holding (SRRK)

March 17, 2025 | markets.businessinsider.com

Scholar Rock announces Phase 3 SAPPHIRE data

March 16, 2025 | markets.businessinsider.com

Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference

March 16, 2025 | businesswire.com

Scholar Rock issues equity awards to new employees

March 16, 2025 | investing.com

Bank of New York Mellon Corp Has $8.97 Million Position in Scholar Rock Holding Co. (NASDAQ:SRRK)

March 15, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHVS, PTGX, CRNX, and SRRK Company Descriptions

Crinetics Pharmaceuticals NASDAQ:CRNX

$34.73 -0.17 (-0.49%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$35.46 +0.73 (+2.09%)

As of 03/28/2025 05:55 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Pharvaris NASDAQ:PHVS

$15.80 +0.23 (+1.48%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$15.80 +0.00 (+0.03%)

As of 03/28/2025 04:05 PM Eastern

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

Protagonist Therapeutics NASDAQ:PTGX

$48.88 -0.56 (-1.13%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$48.88 0.00 (0.00%)

As of 03/28/2025 04:34 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Scholar Rock NASDAQ:SRRK

$32.84 -0.52 (-1.56%)

Closing price 03/28/2025 04:00 PM Eastern

Extended Trading

$32.85 +0.01 (+0.05%)

As of 03/28/2025 04:05 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time